GW&K Investment Management LLC Has $55.89 Million Holdings in Natera, Inc. $NTRA

GW&K Investment Management LLC decreased its holdings in Natera, Inc. (NASDAQ:NTRA) by 41.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 243,967 shares of the medical research company’s stock after selling 169,507 shares during the period. GW&K Investment Management LLC’s holdings in Natera were worth $55,892,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in NTRA. Palladiem LLC acquired a new position in shares of Natera during the 4th quarter worth approximately $31,000. Horizon Investments LLC acquired a new stake in Natera during the 3rd quarter valued at $32,000. Flagship Harbor Advisors LLC bought a new position in Natera during the fourth quarter worth $41,000. Sound Income Strategies LLC increased its holdings in shares of Natera by 20.0% in the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares during the last quarter. Finally, TD Waterhouse Canada Inc. bought a new position in shares of Natera in the fourth quarter valued at about $62,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NTRA has been the subject of a number of research reports. William Blair began coverage on shares of Natera in a research note on Tuesday, April 14th. They set an “outperform” rating for the company. Evercore reiterated an “outperform” rating and issued a $270.00 price target on shares of Natera in a research note on Friday, May 8th. Piper Sandler reissued an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Robert W. Baird set a $265.00 price objective on shares of Natera in a research report on Friday, May 8th. Finally, BTIG Research reduced their price objective on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a report on Monday, May 11th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $256.12.

Natera Price Performance

Shares of NASDAQ:NTRA opened at $222.82 on Wednesday. The company’s 50 day simple moving average is $205.34 and its 200 day simple moving average is $216.16. The stock has a market capitalization of $31.91 billion, a price-to-earnings ratio of -136.70 and a beta of 1.56. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36.

Insider Transactions at Natera

In other news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 159,500 shares of company stock worth $34,664,208. 5.05% of the stock is owned by insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.